Waking up the gut in critically ill patients

Critical Care

Volumn 14, Issue 5, 2010, Pages

  Meier, Juris J ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2;

CRITICALLY ILL PATIENT; HORMONE ACTION; HORMONE RELEASE; HUMAN; INTESTINE MOTILITY; NOTE; PRIORITY JOURNAL; CRITICAL ILLNESS; DRUG EFFECT; GASTROINTESTINAL TRACT; METABOLISM; MULTIPLE ORGAN FAILURE; SECRETION;

CRITICAL ILLNESS; GASTROINTESTINAL TRACT; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MULTIPLE ORGAN FAILURE;

EID: 80053253590     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9079     Document Type: Note

References (17)

1. Deane A, Chapman MJ, Fraser RJL, Horowitz M. Bench-to-bedside review: The gut as an endocrine organ in the critically ill. Crit Care 2010, 14(5):228.
2. Opal SM, LaRosa SP. Year in review 2008: critical care - sepsis. Crit Care 2009, 13:224. 10.1186/cc7945, 19886974.
3. Kang W, Kudsk KA. Is there evidence that the gut contributes to mucosal immunity in humans?. JPEN J Parenter Enteral Nutr 2007, 31:246-258. 17463152, 10.1177/0148607107031003246.
4. Meier JJ, Nauck MA. Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes Metab Res Rev 2005, 21:91-117. 10.1002/dmrr.538, 15759282.
5. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993, 91:301-307. 330027, 8423228, 10.1172/JCI116186.
6. Nauck MA. Is glucagon-like peptide 1 an incretin hormone?. Diabetologia 1999, 42:373-379. 10.1007/s001250051165, 10096792.
7. Meier JJ, Gallwitz B, Schmidt WE, Nauck MA. Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 2002, 440:269-279. 10.1016/S0014-2999(02)01434-6, 12007541.
8. Nauck MA, Meier JJ. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 2005, 128:135-148. 15780433, 10.1016/j.regpep.2004.07.014.
9. Chaikomin R, Doran S, Jones KL, Feinle-Bisset C, O'Donovan D, Rayner CK, Horowitz M. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects. Am J Physiol Endocrinol Metab 2005, 289:E504-E507. 10.1152/ajpendo.00099.2005, 15886226.
10. Nauck MA, Walberg J, Vethacke A, El-Ouaghlidi A, Senkal M, Holst JJ, Gallwitz B, Schmidt WE, Schmiegel W. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regul Pept 2004, 118:89-97. 10.1016/j.regpep.2003.11.003, 14759561.
11. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109:962-965. 10.1161/01.CIR.0000120505.91348.58, 14981009.
12. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993, 36:741-744. 10.1007/BF00401145, 8405741.
13. Meier JJ, Weyhe D, Michaely M, Senkal M, Zumtobel V, Nauck MA, Holst JJ, Schmidt WE, Gallwitz B. Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med 2004, 32:848-851. 10.1097/01.CCM.0000114811.60629.B5, 15090972.
14. Mussig K, Oncu A, Lindauer P, Heininger A, Aebert H, Unertl K, Ziemer G, Haring HU, Holst JJ, Gallwitz B. Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. Am J Cardiol 2008, 102:646-647. 10.1016/j.amjcard.2008.06.029, 18721530.
15. Deane AM, Chapman MJ, Fraser RJ, Burgstad CM, Besanko LK, Horowitz M. The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study. Crit Care 2009, 13:R67. 2717426, 19439067, 10.1186/cc7874.
16. Schmidt WE. The intestine, an endocrine organ. Digestion 1997, 58(Suppl 1):56-58. 10.1159/000201528, 9225094.
17. Mesotten D, Vanhorebeek I, Van den Berghe G. The altered adrenal axis and treatment with glucocorticoids during critical illness. Nat Clin Pract Endocrinol Metab 2008, 4:496-505. 10.1038/ncpendmet0921, 18695699.